Cargando…

Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists

Background: The P2Y(12) receptor antagonist selatogrel is being developed for subcutaneous self-administration with a ready-to-use autoinjector at the onset of acute myocardial infarction (AMI) symptoms. The unique pharmacological profile of selatogrel (fast, potent, and short-acting) can bridge the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsin, Chih-hsuan, Dingemanse, Jasper, Henrich, Andrea, Bernaud, Corine, Gehin, Martine, Krause, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527299/ https://www.ncbi.nlm.nih.gov/pubmed/37759765 http://dx.doi.org/10.3390/biom13091365

Ejemplares similares

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
por: Schilling, Uta, et al.
Publicado: (2022)

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y(12) receptor between selatogrel and oral P2Y(12) antagonists
por: Henrich, Andrea, et al.
Publicado: (2021)

Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel
por: Schilling, Uta, et al.
Publicado: (2020)

The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo
por: Crescence, Lydie, et al.
Publicado: (2021)

Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y(12) receptor antagonist, in patients with chronic coronary syndromes
por: Storey, Robert F, et al.
Publicado: (2019)

Comparison of the effects of the GPIIb-IIIa antagonist Zalunfiban and the P2Y12 antagonist Selatogrel on Platelet Aggregation
por: Curry, Benjamin J., et al.
Publicado: (2023)

Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies
por: Dingemanse, Jasper, et al.
Publicado: (2014)

Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a(1) receptor) antagonist
por: Anliker‐Ort, Marion, et al.
Publicado: (2023)

Assessment of Target Engagement in a First‐in‐Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders
por: Gehin, Martine, et al.
Publicado: (2020)

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm
por: Juif, Pierre-Eric, et al.
Publicado: (2021)

Disposition and Metabolism of Setipiprant, a Selective Oral CRTH2 Antagonist, in Humans
por: Hoch, Matthias, et al.
Publicado: (2013)

Macitentan: entry-into-humans study with a new endothelin receptor antagonist
por: Sidharta, Patricia N., et al.
Publicado: (2011)

Mind the Gap!
por: Lazcano, Antonio
Publicado: (2009)

Mind the Gap
por: Smith, Kirk R., et al.
Publicado: (2010)

Mind the gap
por: Litim, Daniel F.
Publicado: (2001)

Mind the Gap
por: Kohlstedt, Kevin
Publicado: (2016)

Drug Development for Pediatric Populations: Regulatory Aspects
por: Zisowsky, Jochen, et al.
Publicado: (2010)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
por: Sidharta, Patricia N, et al.
Publicado: (2019)

Minding the analytics gap
por: Ransbotham, Sam, et al.
Publicado: (2015)

Vinculin minds the gap
por: Leslie, Mitch
Publicado: (2012)

Yes- mind the gap!
por: Hamsen, Uwe, et al.
Publicado: (2021)

Mind the replication gap
por: Mocanu, Camelia, et al.
Publicado: (2021)

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
por: Fontes, Magda S. C., et al.
Publicado: (2022)

Target switch of centipede toxins for antagonistic switch
por: Yang, Shilong, et al.
Publicado: (2020)

Mind the gap : tracing the origins of human universals
Publicado: (2010)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

Credibility Matters: Mind the Gap
por: Skelly, Andrea C.
Publicado: (2014)

SYNGAP1: Mind the Gap
por: Jeyabalan, Nallathambi, et al.
Publicado: (2016)

Mind the gap: The hospital breakroom
por: Ellsworth, Misti, et al.
Publicado: (2020)

Essential diagnostics: mind the gap
por: The Lancet Global Health
Publicado: (2021)

Confidence and Prediction Intervals for Pharmacometric Models
por: Kümmel, Anne, et al.
Publicado: (2018)

Mind the Gap: A Single-Site, 12-Year Analysis of Trends in Medicine Residents Taking Gap Years before Fellowship
por: Santhosh, Lekshmi, et al.
Publicado: (2023)

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
por: Bruderer, Shirin, et al.
Publicado: (2011)

Mind the gap versus filling the gap. The heart beyond specialties
por: Pascual, Isaac, et al.
Publicado: (2021)

Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects
por: Berger, Benjamin, et al.
Publicado: (2023)

Mind the gap: the transition to hospital consultant
por: Westerman, Michiel
Publicado: (2013)

The is and ought of the Ethics of Neuroenhancement: Mind the Gap
por: Forlini, Cynthia, et al.
Publicado: (2016)

Translating intentions to prescriptions: Mind the gap!
por: Ramakrishnan, Nagarajan
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bve2f3mlemk5osuoolfqjh4neu